Signaling Networks of Nuclear Receptor Transcriptional Crosstalk in Lung Cancer
肺癌核受体转录串扰的信号网络
基本信息
- 批准号:9120927
- 负责人:
- 金额:$ 24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-01 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:AccountingAddressAffinityAgonistBioinformaticsBiologicalBiological AssayBiologyCell LineCellsCommunitiesCyclic AMPDNADNA BindingDataData AnalysesData QualityData SetDiseaseEstrogen Receptor alphaEventFDA approvedFRAP1 geneFamilyGefitinibGenomeGoalsGoldGuiltHealthHela CellsHepG2HumanInformaticsInvestigationLearningLigandsLinkMalignant Epithelial CellMalignant neoplasm of lungMethodologyMethodsMiningNR4A1 geneNon-Small-Cell Lung CarcinomaNuclear ReceptorsOncogenicOutcomePPAR gammaPathologyPathway interactionsPatternPharmacologic SubstancePharmacologyPlayProtein FamilyProteinsProto-Oncogene Proteins c-aktResearchResearch Peer ReviewResearch PersonnelResistanceResponse ElementsRestRoleSignal PathwaySignal TransductionTechniquesTissuesTranscriptional RegulationTranslatingTyrosine Kinase InhibitorWorkbasecancer typedata miningdrug developmentinterestmembernew therapeutic targetprogramsresponsesmall moleculetargeted treatmenttooltranscription factoruser-friendlyweb portal
项目摘要
DESCRIPTION: Nuclear receptors have been proven to be successful as a druggable family of cellular regulators. We learned much of NR biology and pharmacology from very few NRs and their agonist/antagonist ligands. Among these well-studied NRs are ERα, GR, PR, AR, and - more recently - PPARγ. The first four NRs mentioned account for the vast majority of NR-related peer reviewed research and essentially half of FDA-approved NR targeting therapies. There are 48 members of the NR protein family in humans, and much remains to be learned for the rest of the NRs. There are at least two ways to find and prioritize pharmaceutical opportunities for the NR class. One is to find NRs that work synergistically with or regulated by the well-studied NRs and TFs - this constitutes discovery and characterization of transcriptional crosstalk between transcriptional regulators, implying "guilt of association" functions for interactors of known disease targets. The other way is to identify NRs that are activated by the major cellular signaling pathways, or NRs "effectors" of a signaling transduction cascades. To enrich our understanding of the druggable genome, we propose to gather data about dynamics of NR activation and NR crosstalk with other transcription factors (TFs) under different signaling events. Our first major goal (Aim 1) is to learn from NRs with known roles, but not fully characterized mechanisms, in disease. We will use transcription factor response element pulldown (catTFRE) - a method that we recently developed for direct profiling of TF DNA binding activity to their cognate DNA response elements - to find transcriptional effectors (NRs, their coregulators, and other interacting transcription factors) of cellular response to known small molecule modulators of better-studied NRs. A complementary approach is to use catTFRE technique to find NRs, TFs, and coregulators that are activated by 7 major signaling pathways (Aim 2). This study will link signaling events with NR activation and close substantial gaps in understanding of global integrative transcriptional impact of signaling pathways. Aim 2 data will be gathered in the context of lung cancer pathology. Aim 3 develops informatics solutions to address issues in technical and biomedical analysis of data acquired from Aims 1 and 2. Importantly, we will develop user-friendly applications and a web portal for representation and sharing of findings from this proposal.
描述:核受体已被证明是一类可用药的细胞调节剂家族。我们从很少的NRs及其激动剂/拮抗剂配体那里学到了大量的NR生物学和药理学知识。在这些被研究得很好的NRs中有ERα、GR、PR、AR和最近的PPARγ。提到的前四个NRs占了NR相关同行评议研究的绝大多数,基本上占FDA批准的NR靶向疗法的一半。在人类中,有48个NR蛋白家族的成员,对于其余的NR,还有很多东西需要了解。至少有两种方法可以为NR类找到制药机会并确定其优先顺序。一是寻找与研究充分的NRs和TF协同工作或受其调控的NRs--这构成了转录调控因子之间转录串扰的发现和表征,这意味着已知疾病靶标的相互作用者的“关联内疚”功能。另一种方法是识别由主要细胞信号通路激活的NRs,或信号转导级联的NRs“效应器”。为了丰富我们对可药物基因组的理解,我们建议收集关于不同信号事件下NR激活的动态以及NR与其他转录因子(TF)的串扰的数据。我们的第一个主要目标(目标1)是向NRS学习,这些NRS在疾病中具有已知的作用,但尚未完全确定其机制。我们将使用转录因子反应元件下拉(CatTFRE)--我们最近开发的一种直接测定TFDNA与其同源DNA反应元件结合活性的方法--来寻找细胞对已知小分子调节剂的转录效应因子(NRs、其辅助调节因子和其他相互作用的转录因子),这些小分子调节剂是研究得更好的NRs的小分子调节器。一种补充的方法是使用catTFRE技术来寻找由7条主要信号通路激活的NR、TF和辅助调节因子(目标2)。这项研究将把信号事件与NR激活联系起来,并填补在理解信号通路的全球整合转录影响方面的实质性差距。AIM 2的数据将在肺癌病理学的背景下收集。AIM 3开发信息学解决方案,以解决从AIM 1和2获得的数据的技术和生物医学分析方面的问题。重要的是,我们将开发用户友好的应用程序和一个门户网站,用于陈述和分享这项提案的结果。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A proteomics landscape of circadian clock in mouse liver.
小鼠肝脏生物钟的蛋白质组学景观
- DOI:10.1038/s41467-018-03898-2
- 发表时间:2018-04-19
- 期刊:
- 影响因子:16.6
- 作者:Wang Y;Song L;Liu M;Ge R;Zhou Q;Liu W;Li R;Qie J;Zhen B;Wang Y;He F;Qin J;Ding C
- 通讯作者:Ding C
A mouse tissue transcription factor atlas.
- DOI:10.1038/ncomms15089
- 发表时间:2017-04-21
- 期刊:
- 影响因子:16.6
- 作者:Zhou Q;Liu M;Xia X;Gong T;Feng J;Liu W;Liu Y;Zhen B;Wang Y;Ding C;Qin J
- 通讯作者:Qin J
A proteomic landscape of diffuse-type gastric cancer.
弥漫型胃癌的蛋白质组学景观
- DOI:10.1038/s41467-018-03121-2
- 发表时间:2018-03-08
- 期刊:
- 影响因子:16.6
- 作者:Ge S;Xia X;Ding C;Zhen B;Zhou Q;Feng J;Yuan J;Chen R;Li Y;Ge Z;Ji J;Zhang L;Wang J;Li Z;Lai Y;Hu Y;Li Y;Li Y;Gao J;Chen L;Xu J;Zhang C;Jung SY;Choi JM;Jain A;Liu M;Song L;Liu W;Guo G;Gong T;Huang Y;Qiu Y;Huang W;Shi T;Zhu W;Wang Y;He F;Shen L;Qin J
- 通讯作者:Qin J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JUN QIN其他文献
JUN QIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JUN QIN', 18)}}的其他基金
Cell Adhesion and Signaling in Blood and Vascular Cells
血液和血管细胞中的细胞粘附和信号传导
- 批准号:
10471908 - 财政年份:2021
- 资助金额:
$ 24万 - 项目类别:
Project 2- Mechanistic Role of Talin in Cellular Signaling
项目 2 - Talin 在细胞信号转导中的机制作用
- 批准号:
10471913 - 财政年份:2021
- 资助金额:
$ 24万 - 项目类别:
Project 2- Mechanistic Role of Talin in Cellular Signaling
项目 2 - Talin 在细胞信号转导中的机制作用
- 批准号:
10268698 - 财政年份:2021
- 资助金额:
$ 24万 - 项目类别:
Cell Adhesion and Signaling in Blood and Vascular Cells
血液和血管细胞中的细胞粘附和信号传导
- 批准号:
10661620 - 财政年份:2021
- 资助金额:
$ 24万 - 项目类别:
Project 2- Mechanistic Role of Talin in Cellular Signaling
项目 2 - Talin 在细胞信号转导中的机制作用
- 批准号:
10661636 - 财政年份:2021
- 资助金额:
$ 24万 - 项目类别:
Signaling Networks of Nuclear Receptor Transcriptional Crosstalk in Lung Cancer
肺癌核受体转录串扰的信号网络
- 批准号:
8898227 - 财政年份:2014
- 资助金额:
$ 24万 - 项目类别:
Signaling Networks of Nuclear Receptor Transcriptional Crosstalk in Lung Cancer
肺癌核受体转录串扰的信号网络
- 批准号:
8785287 - 财政年份:2014
- 资助金额:
$ 24万 - 项目类别:
Molecular Basis of ILK/PINCH Function in Cell Adhesion
ILK/PINCH 细胞粘附功能的分子基础
- 批准号:
7806538 - 财政年份:2009
- 资助金额:
$ 24万 - 项目类别:
Molecular Basis of ILK/PINCH Function in Cell Adhesion
ILK/PINCH 细胞粘附功能的分子基础
- 批准号:
8235954 - 财政年份:2009
- 资助金额:
$ 24万 - 项目类别:
Molecular Basis of ILK/PINCH Function in Cell Adhesion
ILK/PINCH 细胞粘附功能的分子基础
- 批准号:
7669735 - 财政年份:2009
- 资助金额:
$ 24万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 24万 - 项目类别:
Research Grant